KRAS and pancreatic neoplasm: These demonstrate that LODER-derived siG12D significantly suppresses pancreatic cancer growth, both in vitro and in vivo, and impedes pancreatic tumor growth [50], although all of the past studies with direct KRAS modifications for pancreatic cancer had failed [51].